Net sales 442 million yen (YoY increase of 513.3%), operating loss 813 million yen, net loss 813 million yen. For fiscal 2027, net sales are forecast at 127 million yen with an expected operating loss of 1,773 million yen, indicating a substantial deficit. Future primary revenue sources are expected to include active pharmaceutical ingredient supply revenue and technology access fees from Clarice Biotherapeutics in the U.S., and upfront contract income for a vocal fold scar treatment in Japan. As a material event regarding the going concern assumption, issuance of new shares and share acquisition rights is being considered as fundraising measures and capital policy actions will be implemented.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4884-20261111-03.pdf","jir_short_summary":"Net sales 442 million yen (YoY increase of 513.3%), operating loss 813 million yen, net loss 813 million yen. For fiscal 2027, net sales are forecast at 127 million yen with an expected operating loss of 1,773 million yen, indicating a substantial deficit. Future primary revenue sources are expected to include active pharmaceutical ingredient supply revenue and technology access fees from Clarice Biotherapeutics in the U.S., and upfront contract income for a vocal fold scar treatment in Japan. As a material event regarding the going concern assumption, issuance of new shares and share acquisition rights is being considered as fundraising measures and capital policy actions will be implemented.","jir_summary":"### Business Overview\nKringle Pharma, Inc., as a drug discovery venture focused on its key pipeline, reported a substantial increase in net sales to 442 million yen for the fiscal year ended September 2026, while recording operating, ordinary and net losses. The business consists of a single segment of pharmaceutical development, and clinical development activities progressed, including the start of an additional Phase III trial. Going forward, the company expects to stabilize revenues through API supply and technology access fee income in the U.S. market and contract upfront income for a vocal fold scar treatment in Japan. Issuance of new shares and share acquisition rights is planned as fundraising measures to stabilize cash flow.\n\n### Outlook and Capital Policy\nNet sales for the fiscal year ending September 2027 are forecast to decline significantly to 127 million yen; however, ongoing revenue streams such as technology access fees and milestone income are assumed. Research and development expenses are expected to increase, with projected operating loss of 1,773 million yen, ordinary loss of 1,773 million yen, and net loss of 1,775 million yen. As part of its capital policy, the company has resolved to issue new shares through a third-party allotment and to issue share acquisition rights, with proceeds to be used for U.S. Phase III trial preparation costs, establishment of API manufacturing capabilities, domestic API manufacturing and working capital.","jir_financial_highlights":"Net sales: 442 million yen (YoY increase of 513.3%)\nOperating loss: -813,446 thousand yen (Prior period -909,452 thousand yen)\nOrdinary loss: -810,072 thousand yen (Prior period -914,755 thousand yen)\nNet loss attributable to owners of parent: -813,642 thousand yen (Prior period -916,255 thousand yen)\nTotal assets: 1,977,307 thousand yen (Decrease of -102,056 thousand yen from fiscal year-end)\nEquity ratio: 57.1% (Prior period 61.5% \u2192 57.1%)","jir_category":"","jir_hashtags":"#KringlePharma, #FinancialSummary, #FinancialStatus, #DrugDiscoveryVenture","jir_key_figures":"Net sales: 442 million yen\nOperating loss: -813,446 thousand yen\nNet loss attributable to owners of parent: -813,642 thousand yen","jir_meta_title":"Kringle Pharma, Inc. Financial Summary for FY Sep 2026 | Net Sales 442 million yen, Significant Losses","jir_meta_description":"Summary of Kringle Pharma, Inc.'s financial results for the fiscal year ended September 2026: net sales 442 million yen and operating loss 813 million yen. Future revenue drivers include API supply and technology access fees from Clarice Biotherapeutics in the U.S. and domestic contract income. Capital measures include consideration of new share issuance.","jir_og_title":"Kringle Pharma, Inc. | Financial Summary for FY Sep 2026","jir_og_description":"Financial summary for Kringle Pharma, Inc. Clarification that net sales are 442 million yen, explanation of widening losses and planned fundraising measures.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149832","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n